AEON Biopharma Reports P-II Trial Results of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
Shots:
- The P-II trial evaluating ABP-450 in adults who suffer from fewer than 15 headache days per month and b/w 6-14 migraine days/month in 305 patients across ~60 sites in the US, Canada & Australia
- The results showed that ABP-450 had a treatment effect with mean reductions in MMD of 4.8 & 5.0 days at 150U & 195U doses vs 4.2 days in PBO at 21-24wks. but did not meet statistical significance. In the 2EPs, 69% & 34% at 195U & 150U doses achieved a ≥50% & ≥75% reduction in MMD significant to PBO at 52% & 23%
- In the exploratory EPs of PGI-S, improvements of -0.9 & -1.0 at 150U & 195U doses vs -0.6 & showed a favorable safety profile for episodic migraine. The P-II study will complete the patient’s enrolment of ABP-450 for chronic migraine in Q4’23 & results are expected in H2’24
Ref: Globenewswire | Image: AEON Biopharma
Related News:- AEON Biopharma to Go Public via Priveterra SPAC Merger for ~$475.5M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
